PERSPECTIVE now ONLINE Nature Cancer 'Milestones in tumor vascularization and its therapeutic targeting' ✏️by Michele De Palma & Douglas Hanahan Read it here: doi.org/10.1038/s43018…

Clinical implementation of #AI assist for pathologists to assess breast cancer metastasis led to significant reduction of time and cost. And "making their work more enjoyable" nature.com/articles/s4301… Nature Cancer

With 3 approved epigenetic drug classes and many more under clinical investigation, epigenetic targets are gaining traction. Here, we take survey of developments and hurdles in targeting the cancer epigenome. Thank you Nature Cancer for the opportunity nature.com/articles/s4301…

ONLINE – the Nature Cancer June issue! 🤩 Read on: - tumor vascularization - clinical trials in breast cancer and in sarcoma - precision oncology - DNA replication stress in PDAC - targeting AML with prolyl hydroxylase inhibitor - cancer epigenomes nature.com/natcancer/volu…

Check out new content Nature Cancer "A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance" doi.org/10.1038/s43018… by Judith Sebolt-Leopold's lab

Now Online Nature Cancer "Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer" by Andrea Sottoriva's lab doi.org/10.1038/s43018…

🔔Now online! Check out this research article from Michael Flister, Zoltan Dezso and colleagues on building a translational cancer dependency map for The Cancer Genome Atlas. Read it here: 🔗doi.org/10.1038/s43018…

🚨REVIEW now ONLINE Nature Cancer from Vito Rebecca Vito Rebecca and colleagues: 'Determinants of resistance and response to melanoma therapy' Read it here: 🔗doi.org/10.1038/s43018…

🔔NOW ONLINE! Research article Nature Cancer from Marco Hofmann, Venu Thatikonda and colleagues on targeting SOS1 to enhance the antitumor effects of KRAS-G12C inhibitors by tackling intrinsic and acquired resistance. Read it here: 🔗doi.org/10.1038/s43018…

🚨REVIEW now ONLINE! From Lawrence Fong and co-authors Nature Cancer on γδ T cells as critical anti-tumour immune effectors. Read it here: 🔗doi.org/10.1038/s43018…

🔔Now Online - Analysis Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms by ZeminZhangLab & Sijin Cheng and colleagues nature.com/articles/s4301…

Save the date! Nature Cancer and Nature Communications are hosting the webinar "The #microbiome in #cancer #immunotherapy" with Laurence Zitvogel Nicola Segata Jonathan (Tsoni) Peled Maria Rescigno 📅 Wednesday 18th Sep 2024 ⏰ 10 am ET / 3 pm UK time cassyni.com/events/FfJmtNo…

Save the date! Nature Cancer and Nature Communications are hosting the webinar "The #microbiome in #cancer #immunotherapy" with Laurence Zitvogel Nicola Segata Jonathan (Tsoni) Peled Maria Rescigno 📅 Wednesday 18th Sep 2024 ⏰ 10 am ET / 3 pm UK time cassyni.com/events/FfJmtNo…

🔔New Article ONLINE Ulrike Rauh & Todd Golub and colleagues developed a selective MCL1 inhibitor that is efficacious in hematological and solid tumors and that limits cardiotoxicity via a more rapid clearance of the drug in vivo. 👇 nature.com/articles/s4301…

✏️ONLINE NOW! 'Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial' by Kavita Dhodapkar, Madhav Dhodapkar and colleagues Read it here: doi.org/10.1038/s43018…

🔔New Article! ONLINE NOW Nature Cancer 'Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer' by Jie Li, Wei Zhao and colleagues 🔗doi.org/10.1038/s43018…

NOW ONLINE Nature Cancer 'A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma' ✏️By Florentia Dimitriou, Reinhard Dummer and co-authors doi.org/10.1038/s43018…